HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
PNMeP1LhDCSM9ryK